罗格列酮对2型糖尿病疗效的观察

The effect of rosiglitazone in patients with type 2 diabetes

目的观察罗格列酮对2型糖尿病(T2DM)患者的疗效。方法将40例糖尿病患者,随机分为实验组和对照组,在原治疗基础上,治疗组加服罗格列酮,对照组加服二甲双胍,疗程均为16周。治疗前后监测血糖、糖化血红蛋白(HbAlc)、血脂及血胰岛素水平的变化。结果 (1)两组治疗前糖化血红蛋白(HbA1c)及空腹血糖差异无统计学意义(P>0.05);各组治疗后均低于本组治疗前(P<0.05);治疗组治疗后两指标均低于对照组治疗后(P<0.05)。(2)两组治疗前后空腹胰岛素均无明显变化(P>0.05);对照组治疗前后差异无统计学意义(P>0.05)。(3)两组治疗前血脂三项各指标差异无统计学意义P>0.05);治疗治疗后血脂三项均低于本组治疗前(P<0.05);对照组治疗后无显著变化(P>0.05)。结论罗格列酮有很好的降糖作用,能改善胰岛素抵抗、凋节血脂,对2型糖尿病患者安全有效。

Objective To observe the effect of rosiglitazone in the patients with type 2 diabetes mellitus （DM）. Methods Forty T2DM patients were randomly divided into two groups, series groups （ n = 20） were given routine therapy alone. Based on original treatment, rosiglitazone was administrated in the treatment group and metformin for the control group. The total observation period was 16 weeks. During the treatment, the levels of serum glucore,lipid, insulin and HbAlc were measured. Results The levels of blood glucose and glycosy lated hemoglobin were both decreased （ P 〈 0. 05 ）. The insulin resistance was improved in both groups, but rosiglitazone group was superior to metformin＇s （P 〈 0. 05 ）. The treatment group, the high density lopoprotein cholesterol increased. Conclusion There is an obvious efficacy of rosiglitazone in treating DM. Rosiglitazone is effective in decreasing serum glucose,improving insulin sensitivity and down regulating blood lipid. There is an obvious efficacy of rosiglitazone in treating DM.